Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod

RoccoCapuano; ManuelaAltieri; MirianaConteAlvinoBiseccoAlessandrod’AmbrosioGiovannaDonnarummaElenaGrimaldiNicolaCoppolaNicolaMediciMassimilianoGaldieroGioacchinoTedeschiAntonioGallo

首页> 外文期刊>Journal of neurology >Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod

【24h】

Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod

机译：Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相关主题

摘要

Abstract Background The assessment of the safety and the humoral response to a third booster dose of the BNT162b2 mRNA COVID-19 vaccine is relevant in patients with Multiple Sclerosis (pwMS) treated with Ocrelizumab (OCR) or Fingolimod (FNG).Methods Serum samples were collected from Healthy controls (HCs) and pwMS treated with OCR or FNG at the following time-points: before the first of two vaccine doses (T0); 8 (T1), 16 (T2), 24 (T3) weeks after the first dose; within 8?weeks before (T0b) and after (T1b) the booster dose. IgG antibodies to SARS-CoV-2 trimeric spike protein (Anti-TSP IgG) were quantified and expressed as binding antibody units (BAU)/mL.Results 40 HCs, 28 pwMS on OCR and 19 on FNG were included. At T0b 12 (42.9) pwMS on OCR and 6 (31.6) on FNG were still positive while, at T1b 16 (57.14) pwMS on OCR and 16 (84.2) on FNG, passed the threshold of positivity. The increase of Anti-TSP IgG levels at T1b was higher for: (i) HCs with respect to OCR (p?

著录项

来源
《Journal of neurology》 |2022年第12期|6185-6192|共8页
作者
RoccoCapuano; ManuelaAltieri; MirianaConteAlvinoBiseccoAlessandrod’AmbrosioGiovannaDonnarummaElenaGrimaldiNicolaCoppolaNicolaMediciMassimilianoGaldieroGioacchinoTedeschiAntonioGallo;
展开▼
作者单位

Department of Advanced Medical and Surgical Sciences (DAMSS),University of Campania “Luigi;

Department of Experimental Medicine,University of Campania “Luigi Vanvitelli”;

Department of Mental Health and Public Medicine,University of Campania “Luigi Vanvitelli”Department of Precision Medicine,University of Campania “Luigi Vanvitelli”;

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类神经病学;
关键词
Booster dose; BNT162b2 mRNA vaccine; Ocrelizumab; Fingolimod; COVID-19;

Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod

摘要

著录项

相关主题

期刊订阅